Furthermore, the expression level of SKP2 is negatively associated with the survival of cancer patients—including those with prostate cancer [29], breast cancer [30,31], or lung cancer [32]—suggesting that SKP2 acts as an oncogene. The gene discussed is SKP2; the disease is prostate carcinoma.